1426 IMMUNOGENICITY AND SAFETY OF TWO DOSES OF INVESTIGATIONAL HEPLISAV™ COMPARED TO THREE DOSES OF LICENSED HEPATITIS B VACCINE (ENGERIX-B®) IN TWO PHASE 3 TRIALS

Autor:	J. Martin, S. Bennett, H. Namini, W. Heyward, R. Janssen
Rok vydání:	2013
Předmět:	Hepatitis B vaccine Hepatology business.industry Immunogenicity Medicine business Virology
Zdroj:	Journal of Hepatology. 58:S574
ISSN:	0168-8278
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::feeddf1f9ed87fa0ba7f3aa7db4f39bc https://doi.org/10.1016/s0168-8278(13)61425-7 Zobrazit plný text záznamu Full Text from ScienceDirect